Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.36 |
| ▸ | DUT | P33316 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8318351 | 0.75 | PSEN1 (0.47) | SLC6A2SLC6A4S1PR4S1PR1S1PR3 | |
| SCHEMBL3286860 | 0.72 | MMP13 (0.38) | SMN1; SMN2SLC6A2SLC6A4BRD4CREBBP | |
| SCHEMBL28735726 | 0.69 | HRH3 (0.48) | SMN1; SMN2 | |
| SCHEMBL4266551 | 0.68 | SMYD2 (0.38) | SMYD2DUTCYP3A4HTTSMN1; SMN2 | |
| SCHEMBL15566115 | 0.67 | SMYD2 (0.37) | SMYD2DUTCYP3A4HTTSMN1; SMN2 | |
| SCHEMBL8422084 | 0.67 | SMYD2 (0.40) | SMYD2DUTCYP3A4HTTSMN1; SMN2 | |
| SCHEMBL2508018 | 0.66 | SMYD2 (0.39) | SMYD2DUTCYP3A4HTTSMN1; SMN2 | |
| SCHEMBL702653 | 0.66 | LTA4H (0.42) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL12988701 | 0.66 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL5030590 | 0.66 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718652-B2 | Substituted benzothiadiazinedioxide derivatives and methods of their use | WYETH LLC (US) | 2010-05-18 | — | — | US | disclosed |
| US-20080161295-A1 | SUBSTITUTED BENZOTHIADIAZINEDIOXIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-07-03 | — | — | US | disclosed |
| WO-2008073958-A2 | SUBSTITUTED BENZOTHIADIAZINEDIOXIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161295-A1 | SUBSTITUTED BENZOTHIADIAZINEDIOXIDE DERIVATIVES AND METHODS OF THEIR USE | SLC6A2, SLC6A4, DBH | SMYD2 1029/4885DUT 1945/4885CYP3A4 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.